Thursday, 2 July 2020

Sun Pharma announces Japan MHLW approval of ILUMYATM for the treatment of Plaque Psoriasis

Sun Pharma and includes its subsidiaries and/or associate companies) announced that one of its wholly-owned subsidiaries has received approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for ILUMYA (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies. Japan has approximately 430,000 people currently suffering from psoriasis.



source https://www.pharmatutor.org/pharma-news/2020/sun-pharma-announces-japan-mhlw-approval-of-ilumyatm-for-the-treatment-of-plaque-psoriasis

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...